HDAC9 and graft versus host disease: expanded upon the mechanism of HDAC inhibition for GVHD by reporting that pretreatment of DCs with HDAC inhibitors could reduce TLR-mediated secretion of proinflammatory cytokines, increase indoleamine 2,3-dioxygenase (IDO) and suppress activation markers CD40 and CD80 (120).